Baird raised the firm’s price target on Boston Scientific to $63 from $60 and keeps an Outperform rating on the shares. The firm raised their out-year estimates and price target following the company’s Analyst Day, where management laid out a best-in-class top-line organic growth outlook, coming in ahead of consensus and investors’ expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
- Boston Scientific signs agreement to acquire Relievant Medsystems
- Boston Scientific has ‘compelling’ pipeline ahead of investor day, says CL King
- Boston Scientific’s Watchman FLX device approved by FDA
- Unusually active option classes on open August 29th